Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunological adjuvants: desirable properties and side-effects.

A C Allison1, N E Byars

  • 1Department of Immunology, Syntex Research, Palo Alto, CA 94002.

Molecular Immunology
|March 1, 1991
PubMed
Summary

A novel adjuvant formulation, Syntex Adjuvant Formulation, combines a stable emulsion with a muramyl dipeptide analog to enhance vaccine efficacy against infectious diseases and tumors while minimizing side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Observational, hypothesis-driven and genomics research strategies for analyzing inherited differences in responses to infectious diseases.

Public health genomics·2012
Same author

Diannexin, an annexin A5 homodimer, binds phosphatidylserine with high affinity and is a potent inhibitor of platelet-mediated events during thrombus formation.

Journal of thrombosis and haemostasis : JTH·2012
Same author

Disc angiogenesis assay.

Methods in molecular medicine·2011
Same author

Diannexin, a novel annexin V homodimer, protects rat liver transplants against cold ischemia-reperfusion injury.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2007
Same author

Mechanisms of action of mycophenolate mofetil.

Lupus·2005
Same author

Mechanisms of action of mycophenolate mofetil in preventing chronic rejection.

Transplantation proceedings·2002

Area of Science:

  • Immunology
  • Vaccinology
  • Biotechnology

Background:

  • Adjuvants are crucial for eliciting robust immune responses and specific antibody isotypes with recombinant antigens.
  • Ideal adjuvants must avoid adverse reactions like pyrogenicity, uveitis, or arthritis.
  • Muramyl dipeptide (MDP) analogs are potent adjuvants, but their efficacy needs to be balanced against potential side effects.

Purpose of the Study:

  • To develop and evaluate a novel adjuvant formulation, Syntex Adjuvant Formulation (SAF).
  • To assess the safety and efficacy of SAF in enhancing immune responses to various vaccines.
  • To identify an MDP analog with a favorable safety profile for use in vaccine formulations.

Main Methods:

  • Screening of 130 muramyl dipeptide analogs to identify N-acetylmuramyl-L-threonyl-D-isoglutamine for optimal adjuvant potency and safety.

Related Experiment Videos

  • Development of a stable emulsion vehicle using squalane and Pluronic L-121 for antigen targeting.
  • Combination of the selected MDP analog with the emulsion to create the Syntex Adjuvant Formulation.
  • Testing the efficacy of SAF with influenza, hepatitis B virus, herpes simplex virus, lentivirus, and tumor vaccines in experimental animal models.

    • Main Results:

    • N-acetylmuramyl-L-threonyl-D-isoglutamine demonstrated a superior separation between adjuvant potency and side-effect induction compared to other MDP analogs.
    • The squalane-Pluronic L-121 emulsion effectively targeted antigens to antigen-presenting cells.
    • Syntex Adjuvant Formulation significantly enhanced the efficacy of multiple vaccines, including those for influenza, hepatitis B, herpes simplex virus, lentivirus, and tumors, in preclinical studies.

    Conclusions:

    • Syntex Adjuvant Formulation represents a promising new adjuvant system for improving vaccine effectiveness.
    • The formulation offers a favorable safety profile, reducing the risk of adverse reactions associated with traditional adjuvants.
    • SAF has broad applicability for enhancing the immunogenicity of diverse vaccine candidates, paving the way for improved preventative strategies against infectious diseases and cancer.